Article

A systematic review of low-dose interleukin-2 for the treatment of systemic lupus erythematosus

2022-12-04

Abstract excerpt

<h4>Background</h4> Low-dose interleukin-2 (IL-2) shows promise as a treatment for restoring functional and numerical deficits of regulatory T (Treg) cells in patients with various autoimmune diseases. Several clinical trials testing low-dose IL-2 in systemic lupus erythematosus (SLE) have been completed, with a comprehensive review of these trials currently lacking. <h4>Objective</h4> We aimed to conduct a system...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 008591dd-0ee3-5c2c-b68f-9b12fe9faeb9
DOI: 10.1101/2022.12.02.22283038

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A systematic review of low-dose interleukin-2 for the treatment of systemic lupus erythematosusDOI 10.1101/2022.12.02.22283038Read

Safety, Pharmacokinetics, Biomarker Response, and Efficacy of E6742, a Dual Antagonist of Toll-Like Receptors 7 and 8, in a First-in-Patient, Randomized, Double-Blind, Phase 1/2 Study in Systemic Lupus ErythematosusSemantic proximity Read

Efficacy and safety of belimumab in immune thrombocytopenia secondary to systemic lupus erythematosusSemantic proximity Read

Interleukin-2 immunotherapy reveals human regulatory T cell subsets with distinct functional and gatekeeper featuresSemantic proximity Read

Low-dose IL-2 reduces IL-21+ T cell frequency and induces anti-inflammatory gene expression in type 1 diabetesSemantic proximity Read

Double-Edged Sword: Interleukin-2 Promotes T Regulatory Cell Differentiation but Also Expands Interleukin-13- and Interferon-γ-Producing CD8+ T Cells via STAT6-GATA-3 Axis in Systemic Lupus Erythematosus.Semantic proximity Read

Categorization of Patients With Systemic Lupus Erythematosus Using Disease Activity, Patient-Reported Outcomes and Transcriptomic SignaturesSemantic proximity Read

Resolvin D1 Improves the Treg/Th17 Imbalance in Systemic Lupus Erythematosus Through miR-30e-5pSemantic proximity Read

Methotrexate and Prednisolone compared to placebo and prednisolone in the treatment of Erythema Nodosum Leprosum - an international multicentre, double-blind randomised controlled clinical trial - MaPs in ENLSemantic proximity Read

Efficacy and safety of belimumab combined with the standard regimen in treating children with lupus nephritisSemantic proximity Read

The Future of Systemic Lupus Erythematosus Treatment: The Promise of Selective Immunotherapies, Anifrolumab and Belimumab, Compared to Blanket ImmunosuppressivesSemantic proximity Read

Mesenchymal Stem Cell Therapy: Hope for Patients With Systemic Lupus Erythematosus.Semantic proximity Read

Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infectionSemantic proximity Read